ASX:SOMSomnomed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Somnomed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$1.08 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$1.06Now: A$1.08▼A$1.1050-Day RangeA$1.02MA: A$1.12▼A$1.3252-Week RangeA$0.90Now: A$1.08▼A$3.44Volume95,124 shsAverage VolumeN/AMarket Capitalization$79.01 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Australia and internationally. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Somnomed. Previous Next 0.0 Community Rank Outperform VotesSomnomed has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSomnomed has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Somnomed and other stocks. Vote “Outperform” if you believe SOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SOM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSomnomed does not currently pay a dividend.Dividend GrowthSomnomed does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Somnomed insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Somnomed are expected to decrease by -100.00% in the coming year, from A$0.05 to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Somnomed is -19.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Somnomed is -19.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSomnomed has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.00 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolASX:SOM Previous Symbol CUSIPN/A CIKN/A Websomnomed.com Phone61 2 9467 0400Debt Debt-to-Equity Ratio52.11 Current Ratio1.34 Quick Ratio1.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio20.40 P/E GrowthN/A Sales & Book Value Annual Sales$63.33 million Price / Sales1.25 Cash FlowA$0.14 per share Price / Cash Flow7.61 Book ValueA$0.32 per share Price / Book3.38Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares73,156,496Market Cap$79.01 million Next Earnings DateN/A OptionableNot Optionable Receive SOM News and Ratings via Email Sign-up to receive the latest news and ratings for SOM and its competitors with MarketBeat's FREE daily newsletter. Somnomed (ASX:SOM) Frequently Asked Questions Has Somnomed been receiving favorable news coverage? News headlines about SOM stock have been trending somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Somnomed earned a daily sentiment score of -1.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutSomnomed. Who are some of Somnomed's key competitors? Some companies that are related to Somnomed include Creo Medical Group (CREO), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Advanced Oncotherapy (AVO), Resonance Health (RHT), Kromek Group (KMK), REVA Medical (RVA), Total Brain (TTB), EMvision Medical Devices (EMV) and MRI Interventions (MRIC). View all competitors. Who are Somnomed's key executives? Somnomed's management team includes the following people: Mr. Neil Verdal-Austin, Chief Exec. OfficerMr. Hervé Fiévet, Chief Financial OfficerMr. Martin Weiland, Exec. VP of Sales and Marketing - EuropeMr. Kien T. Nguyen, Exec. Pres of North AmericaDr. Jagdeep Bijwadia, Chief Medical Officer What is Somnomed's stock symbol? Somnomed trades on the ASX under the ticker symbol "SOM." What is Somnomed's stock price today? One share of SOM stock can currently be purchased for approximately A$1.08. How big of a company is Somnomed? Somnomed has a market capitalization of $79.01 million and generates $63.33 million in revenue each year. What is Somnomed's official website? The official website for Somnomed is somnomed.com. How can I contact Somnomed? The company can be reached via phone at 61 2 9467 0400. This page was last updated on 5/30/2020 by MarketBeat.com Staff
